How to Help Your Patients Find Valganciclovir in Stock: A Provider's Guide

Transplant coordinators and infectious disease specialists know the scenario all too well: a patient calls, panicked, because they just picked up a new prescription for valganciclovir and six pharmacies have told them they don't carry it. The patient is a week post-discharge from a kidney transplant. Every hour without CMV prophylaxis carries risk.

This guide is designed to help clinicians, transplant coordinators, and clinical pharmacists build systems that prevent these moments — and respond effectively when they happen anyway.

Understanding Why Patients Can't Find Valganciclovir

Valganciclovir is not in FDA shortage as of 2026. The issue is structural. It is a high-cost specialty drug — generic tablets retail for over $3,000/month without a coupon, and brand Valcyte is even higher — dispensed primarily through specialty pharmacies that serve transplant and HIV populations. Most retail chain pharmacies don't stock it.

When a patient is discharged from a transplant center and tries to fill valganciclovir at their local pharmacy without preparation, they frequently hit a dead end. Your clinical systems can close this gap before it becomes a patient emergency.

Pre-Discharge Checklist: Setting Patients Up for Success

The most effective intervention is the one that happens before the patient leaves the hospital. Consider building the following into your discharge workflow:

1. Identify the patient's outpatient pharmacy before discharge and verify it can dispense valganciclovir. This should be a specialty pharmacy (Accredo, CVS Specialty, AllianceRx, Optum Rx Specialty, or your center's affiliated pharmacy).
2. Submit prior authorization (PA) before discharge. PA for valganciclovir is required by most commercial payers and many Part D plans. Starting this process a day or two before discharge prevents a 3–5 business day gap at home.
3. Dispense a bridge supply from the inpatient pharmacy. A 5–7 day supply covers the time the specialty pharmacy needs to process the first outpatient fill. This is one of the highest-impact, lowest-cost interventions to prevent CMV prophylaxis gaps.
4. Educate the patient: Tell them explicitly not to go to their regular retail pharmacy unless it is confirmed to carry valganciclovir. Provide the specialty pharmacy's name and phone number in writing.
5. For pediatric patients: Confirm the pharmacy can handle oral solution dispensing, which requires reconstitution. Note that the constituted oral solution must be refrigerated and is only stable for 49 days — plan dispensing quantities accordingly.

Managing Prior Authorization for Valganciclovir

Prior authorization for valganciclovir typically requires documentation of:

• Type of transplant (solid organ vs. bone marrow) and date of transplant
• CMV serologic status of donor and recipient (D+/R- is particularly well supported)
• Prescribed duration and dose (renal function-adjusted)
• For CMV retinitis in AIDS patients: documentation of HIV/AIDS status, CMV diagnosis, and ophthalmic assessment

Appeals for denied PAs should emphasize the FDA-approved indication, the patient's documented high-risk CMV status (D+/R-), and published guidelines from AST, IDSA, and ASHP supporting prophylaxis in the approved patient population. Peer-to-peer reviews should involve the transplant physician directly whenever possible.

What to Do When a Patient Calls Saying They Can't Find It

When a patient contacts your office unable to fill valganciclovir:

1. Determine whether the issue is a stock problem or a PA/coverage problem. These require completely different solutions.
2. For stock problems: direct the patient to your transplant pharmacy or specialty pharmacy partner. For urgent situations, consider an emergency inpatient pharmacy dispense if the patient can come in.
3. For PA/coverage problems: initiate an emergency PA or peer-to-peer review. Some plans will authorize a 72-hour emergency supply while the PA is under review.
4. For financial problems: explore Genentech's patient assistance program for Valcyte, NeedyMeds, or Ryan White HIV/AIDS Program funding if applicable.

Patient-Facing Tools to Recommend

For patients who are not enrolled in a specialty pharmacy and are struggling to find valganciclovir, medfinder is a service that calls local pharmacies on the patient's behalf to identify which ones can fill the prescription. The patient provides their medication and location; medfinder does the calling and texts results. This can be especially valuable in the first days post-discharge when specialty pharmacy enrollment hasn't completed yet.

Related provider resource: Valganciclovir Shortage: What Providers and Prescribers Need to Know in 2026.